Ligand Pharmaceuticals (LGND) Times Interest Earned (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Times Interest Earned of $1.17 for Q1 2026, down 99.81% sequentially from $629.23 in Q4 2025, and up 102.79% YoY from $0.57 in Q1 2025.
Ligand Pharmaceuticals (LGND) Times Interest Earned (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Times Interest Earned for 17 years, with the latest figure at $1.17 in Q1 2026.
- Quarterly Times Interest Earned rose 102.79% year-over-year to $1.17 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.35 (up 158.04% YoY) and the FY2025 annual result came in at $1.3, up 509.83% from the prior year.
- Times Interest Earned eased to $1.17 in Q1 2026 per LGND's latest filing, from $629.23 in the prior quarter.
- Over five years, Times Interest Earned peaked at $3078.0 in Q3 2023 and troughed at -$83.75 in Q4 2022.
- A 5-year average of $222.94 and a median of $3.69 in 2025 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned sank 3196.71% in 2024, then soared 18218.77% in 2025.
- Over 5 years, Times Interest Earned stood at -$83.75 in 2022, then jumped by 96.39% to -$3.02 in 2023, then decreased by 15.0% to -$3.47 in 2024, then jumped by 18218.77% to $629.23 in 2025, then tumbled by 99.81% to $1.17 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered $1.17, $629.23, and $3.69 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 0.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.26 |
| Mar 31, 2026 | 1.17 |
| Dec 31, 2025 | 629.23 |
| Sep 30, 2025 | 3.69 |
| Jun 30, 2025 | 81.19 |
| Mar 31, 2025 | -41.77 |
| Dec 31, 2024 | -3.47 |
| Sep 30, 2024 | 4.24 |
| Jun 30, 2024 | -15.06 |
| Mar 31, 2024 | 21.19 |
| Dec 31, 2023 | -3.02 |
| Sep 30, 2023 | 3,078.00 |
| Jun 30, 2023 | -0.46 |
| Mar 31, 2023 | 59.19 |
| Dec 31, 2022 | -83.75 |
| Sep 30, 2022 | 37.17 |
| Jun 30, 2022 | 19.78 |
| Mar 31, 2022 | 2.70 |
| Dec 31, 2021 | 8.44 |
| Sep 30, 2021 | 3.54 |